Mr.Hotsia Travel with Health

How does psoriasis increase gout prevalence, supported by systemic inflammation studies, and how do biologic therapies compare with standard urate-lowering treatments?

Psoriasis significantly increases the prevalence of gout, a painful inflammatory arthritis, through a shared pathway of chronic systemic inflammation. The rapid skin cell turnover in psoriasis leads to an overproduction of uric acid, a waste product that can crystallize in the joints and trigger a gout attack.

🔥 Psoriasis and Gout: A Shared Inflammatory Pathway

The connection between psoriasis and an increased prevalence of gout is deeply rooted in the chronic systemic inflammation that characterizes psoriasis. Psoriasis is much more than just a skin disease; it is an autoimmune condition that creates a state of persistent, low-grade inflammation throughout the body. This inflammatory environment is a key factor in the development of hyperuricemia (high levels of uric acid in the blood), which is the precursor to gout.

There are two primary mechanisms by which psoriasis leads to an increased risk of gout:

1. Increased Uric Acid Production: Psoriasis is characterized by hyperproliferation, an accelerated rate of skin cell turnover. As these cells are rapidly produced and broken down, there is an increased breakdown of purines, which are components of the cells’ genetic material. The metabolism of these purines results in the production of uric acid as a final waste product. This overproduction can overwhelm the body’s ability to excrete the uric acid, leading to elevated levels in the bloodstream.
2. Inflammation-Induced Hyperuricemia: The systemic inflammation in psoriasis can also independently contribute to hyperuricemia. Inflammatory cytokines, which are signaling molecules of the immune system that are abundant in psoriasis, can interfere with the kidneys’ ability to excrete uric acid. This decreased renal clearance further exacerbates the problem of high uric acid levels.

Systemic inflammation studies have confirmed this link by showing that patients with psoriasis have higher levels of inflammatory markers, such as C-reactive protein (CRP), and that these levels are correlated with higher serum uric acid levels. The evidence is clear: psoriasis creates the perfect storm for the development of gout by both increasing the production and decreasing the excretion of uric acid. This is why individuals with psoriasis, particularly those with more severe disease or psoriatic arthritis, have a significantly higher prevalence of gout compared to the general population.

⚖️ Biologic Therapies vs. Standard Urate-Lowering Treatments

When it comes to managing gout in a patient who also has psoriasis, the treatment approach can be complex. There are two main classes of medications to consider: biologic therapies, which target the underlying inflammation of psoriasis, and standard urate-lowering treatments (ULT), which directly target the high uric acid levels of gout.

Biologic therapies are a class of drugs that are designed to target specific components of the immune system that are involved in the inflammatory cascade of psoriasis. These medications, such as TNF-alpha inhibitors (e.g., adalimumab, etanercept) and interleukin inhibitors (e.g., ustekinumab, secukinumab), can be highly effective in clearing the skin and reducing the joint inflammation of psoriatic arthritis.

Interestingly, by reducing the overall systemic inflammation, some of these biologic therapies can have a secondary, beneficial effect on uric acid levels. TNF-alpha inhibitors, in particular, have been shown in some studies to lower serum uric acid levels and reduce the risk of gout flares. By controlling the underlying driver of both the skin disease and the hyperuricemia, biologics can offer a unified treatment approach.

Standard urate-lowering treatments (ULT) are the cornerstone of gout management. These medications are not designed to treat psoriasis; their sole focus is on reducing the amount of uric acid in the body. The most common types of ULT are:

• Xanthine oxidase inhibitors (e.g., allopurinol, febuxostat): These drugs work by blocking the enzyme that is responsible for producing uric acid.
• Uricosuric agents (e.g., probenecid): These drugs work by increasing the excretion of uric acid by the kidneys.

ULT is highly effective at lowering uric acid levels to the target range (typically below 6 mg/dL), which prevents the formation of uric acid crystals and, over time, can dissolve existing crystals.

In a direct comparison:

• Primary Target: Biologic therapies target the inflammation of psoriasis, with a secondary effect on uric acid. Standard ULT directly targets uric acid levels, with no direct effect on the skin or joint inflammation of psoriasis.
• Scope of Treatment: Biologics offer a single treatment for both conditions, which can be a major advantage in terms of simplifying the medication regimen. Standard ULT only treats the gout component.
• Efficacy: For a patient with severe psoriasis and gout, a biologic may be the preferred initial choice as it addresses the root cause of the systemic inflammation. However, if the uric acid levels remain high despite treatment with a biologic, or if the gout is particularly severe, adding a standard ULT is often necessary. The two are not mutually exclusive and are frequently used in combination.
• Clinical Guidelines: Current clinical guidelines recommend that all patients with psoriasis be screened for hyperuricemia. If a patient has both active psoriasis and gout, the choice of a biologic that is known to have a favorable effect on uric acid levels is a logical consideration. However, the definitive treatment for gout remains the lowering of uric acid to the target level, and this is most reliably and powerfully achieved with standard ULT.

In conclusion, for a patient with the dual diagnosis of psoriasis and gout, an integrated and collaborative approach between a rheumatologist and a dermatologist is ideal. While biologic therapies offer a compelling option to treat the shared inflammatory pathway of both diseases, standard urate-lowering therapy remains the most direct and effective tool for managing the hyperuricemia that causes gout. The optimal strategy often involves using a biologic to control the psoriasis and the systemic inflammation, supplemented with a standard ULT to ensure that the uric acid levels are brought down to a safe and therapeutic level.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com